Abstract
Heart rate is a major determinant of cardiac output and myocardial oxygen utilization and is increasingly being nominated as a modifiable risk factor for cardiovascular disease. Despite this evidence, screening strategies for preventing cardiovascular diseases do not include routine assessment of resting heart rate. Reasonably, heart rate reduction has been suggested as a useful approach against angina pectoris in subjects with acute or chronic coronary syndromes. Accordingly, reduction of heart rate in patients with stable angina could be an additional goal of therapy. Important data have shown retrospectively the beneficial effect of heart rate-lowering drugs, such as betaadrenoceptor antagonists, non-dihydropyridine calcium channel antagonists, as well as other agents, on several parameters in patients with coronary artery disease and stable angina. However, additional data are now being sought to assess the impact of this approach on clinical practice.
Keywords: Stable angina, heart rate, therapeutic target, beta-blockers, ivabradine, ranolazine, cardiac output, myocardial oxygen, cardiovascular diseases, non-dihydropyridine calcium channel
Current Pharmaceutical Design
Title:Heart Rate as a Therapeutic Target in Angina Pectoris
Volume: 19 Issue: 9
Author(s): Emmanuel Androulakis, Dimitris Tousoulis, Nikolaos Papageorgiou, Anna Kontogeorgou, Alexandros Briasoulis, Marietta Charakida, Gerasimos Siasos, Evangelos Oikonomou, Katerina Siama, George Latsios and Christodoulos Stefanadis
Affiliation:
Keywords: Stable angina, heart rate, therapeutic target, beta-blockers, ivabradine, ranolazine, cardiac output, myocardial oxygen, cardiovascular diseases, non-dihydropyridine calcium channel
Abstract: Heart rate is a major determinant of cardiac output and myocardial oxygen utilization and is increasingly being nominated as a modifiable risk factor for cardiovascular disease. Despite this evidence, screening strategies for preventing cardiovascular diseases do not include routine assessment of resting heart rate. Reasonably, heart rate reduction has been suggested as a useful approach against angina pectoris in subjects with acute or chronic coronary syndromes. Accordingly, reduction of heart rate in patients with stable angina could be an additional goal of therapy. Important data have shown retrospectively the beneficial effect of heart rate-lowering drugs, such as betaadrenoceptor antagonists, non-dihydropyridine calcium channel antagonists, as well as other agents, on several parameters in patients with coronary artery disease and stable angina. However, additional data are now being sought to assess the impact of this approach on clinical practice.
Export Options
About this article
Cite this article as:
Androulakis Emmanuel, Tousoulis Dimitris, Papageorgiou Nikolaos, Kontogeorgou Anna, Briasoulis Alexandros, Charakida Marietta, Siasos Gerasimos, Oikonomou Evangelos, Siama Katerina, Latsios George and Stefanadis Christodoulos, Heart Rate as a Therapeutic Target in Angina Pectoris, Current Pharmaceutical Design 2013; 19(9) . https://dx.doi.org/10.2174/1381612811319090003
DOI https://dx.doi.org/10.2174/1381612811319090003 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |

- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility Of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
- Forthcoming Thematic Issues
Related Articles
-
An Overview of Innovations in Analysis and Beneficial Health Effects of Wine Polyphenols
Mini-Reviews in Medicinal Chemistry Editorial from Editor-in-Chief (Adherence to CPAP: Understanding the Key to a Successful Treatment)
Current Respiratory Medicine Reviews The Coronin Family and Human Disease
Current Protein & Peptide Science Piribedil: Antiparkinsonian Properties and Potential Clinical Utility in Dopaminergic Disorders
Current Drug Therapy Implementation of Cardiovascular Disease Prevention Guidelines into Clinical Practice: an Unmet Challenge?
Current Pharmaceutical Design Mutations of mtDNA in some Vascular and Metabolic Diseases
Current Pharmaceutical Design Taurine, Bone Growth and Bone Development
Current Nutrition & Food Science Short- and Long-Term Survival of Nonsurgical Intensive Care Patients and its Relation to Diagnosis, Severity of Disease, Age and Comorbidities
Current Aging Science Association Between Polycystic Ovary Syndrome and Metabolic Syndrome
Current Medicinal Chemistry Repair of Dilated Aortic Root and Sinotubular Junction Using a Stabilizer Ring
Recent Patents on Cardiovascular Drug Discovery Psychoemotional Background of Temporomandibular Joint Dysfunction and Possible Drug Therapy
Letters in Drug Design & Discovery Molecular Determinants of the Cardiometabolic Phenotype
Endocrine, Metabolic & Immune Disorders - Drug Targets Nutraceuticals and Dietary Supplements to Improve Quality of Life and Outcomes in Heart Failure Patients
Current Pharmaceutical Design Efficient Chemical Synthesis of a Scutellarein Derivative Containing Morpholine Ring
Letters in Organic Chemistry Key Sites for P2X Receptor Function and Multimerization: Overview of Mutagenesis Studies on a Structural Basis
Current Medicinal Chemistry Cardiovascular Proteomics
Current Proteomics Drug-Related Cardiotoxicity for the Treatment of Haematological Malignancies in Elderly
Current Pharmaceutical Design Fatty Acid Intakes and Coronary Heart Disease Mortality in Japan: NIPPON DATA90, 1990-2005
Current Nutrition & Food Science The Effects of Vitamin B in Depression
Current Medicinal Chemistry Gender Differences in Non-Obstructive Coronary Artery Disease
Current Pharmaceutical Design